The major symptoms of Ménière’s disease are episodic vertigo, fluctuating hearing loss, and tinnitus. Direction-changing spontaneous nystagmus is a characteristic vestibular finding in Ménière’s disease. In the acute stage, spontaneous nystagmus beating to the affected side (irritative nystagmus) is often observed, while paralytic nystagmus beating to the healthy side is found in the chronic stage. This direction-changing nystagmus can be reproduced in guinea pigs by increasing the potassium ion concentration in the perilymph. The objectives of the present study were to examine the effects of increasing the potassium ion concentration of the rat perilymph on hearing and nystagmus. Under isoflurane anesthesia, 22 rats received intratympanic injection of different concentrations of potassium chloride (KCl) solution or distilled water: groups 1, 2, 3, and 4 received saturated (3.4 M) KCl solution, 2 M KCl, 1 M KCl, and distilled water, respectively. The nystagmus direction and number per 15 s were monitored for 150 min. In the other 8 rats, hearing was monitored 30 min and 20 h after intratympanic injection of 2 M KCl (group 5) or distilled water (group 6) using the auditory brainstem responses. Rats in groups 1 and 2 showed spontaneous irritative nystagmus beating to the affected ear followed by paralytic nystagmus beating to the contralateral side. In group 3, irritative nystagmus occurred but paralytic nystagmus was rarely observed. Rats in group 4 showed no nystagmus. Rats in group 5 showed significant hearing impairment 30 min after KCl injection that recovered 20 h later. Control animals in group 6 showed no significant changes in hearing. The reversible hearing impairment with direction-changing spontaneous nystagmus induced by potassium injection into the tympanic cavity in rats was quite similar to that observed in acute Ménière’s attacks. This rat model could be used for basic research investigating the pathophysiological mechanisms underlying Ménière’s attacks.

1.
Albera
R
,
Canale
A
,
Cassandro
C
,
Albera
A
,
Sammartano
AM
,
Dagna
F
.
Relationship between hearing threshold at the affected and unaffected ear in unilateral Meniere’s disease
.
Eur Arch Otorhinolaryngol
.
2016
Jan
;
273
(
1
):
51
6
.
[PubMed]
0937-4477
2.
Bance
M
,
Mai
M
,
Tomlinson
D
,
Rutka
J
.
The changing direction of nystagmus in acute Menière’s disease: pathophysiological implications
.
Laryngoscope
.
1991
Feb
;
101
(
2
):
197
201
.
[PubMed]
0023-852X
3.
Dohlman
GF
.
Further remarks on the mechanism producing the symptoms of Ménière’s disease
.
J Otolaryngol
.
1980
Aug
;
9
(
4
):
285
90
.
[PubMed]
0381-6605
4.
Dohlman
GF
.
Mechanism of the Ménière attack
.
ORL J Otorhinolaryngol Relat Spec
.
1980
;
42
(
1-2
):
10
9
.
[PubMed]
0301-1569
5.
Fukuoka
K
.
[Influence of iontophoresed K+ on vestiburocochlear sensory cells and function]
.
[in Japanese]
.
Nippon Jibiinkoka Gakkai Kaiho
.
1987
Jan
;
90
(
1
):
90
9
.
[PubMed]
0030-6622
6.
Hallpike
CS
,
Cairns
H
.
Observations on the pathology of Meniere’s syndrome
.
Proc R Soc Med
.
1938
Sep
;
31
(
11
):
1317
36
.
[PubMed]
0035-9157
7.
Hozawa
K
,
Takasaka
T
,
Kawamoto
K
,
Fukuoka
K
,
Usami
S
,
Hozawa
J
.
Effect of high perilymphatic potassium concentration on the guinea pig vestibular sensory epithelium
.
Acta Otolaryngol Suppl
.
1987
;
435
sup435
:
21
6
.
[PubMed]
0365-5237
8.
Ikeno
K
.
[Serial change of perilymphatic potassium ion concentration in the scala tympani after introducing KCl-solution into the guinea pigs’ tympanic cavity]
.
[in Japanese]
.
Nippon Jibiinkoka Gakkai Kaiho
.
1990
Sep
;
93
(
9
):
1307
13
.
[PubMed]
0030-6622
9.
Kingma
CM
,
Wit
HP
.
The effect of changes in perilymphatic K+ on the vestibular evoked potential in the guinea pig
.
Eur Arch Otorhinolaryngol
.
2010
Nov
;
267
(
11
):
1679
84
.
[PubMed]
0937-4477
10.
Kitahara
T
,
Takeda
N
,
Saika
T
,
Kubo
T
,
Kiyama
H
.
Effects of MK801 on Fos expression in the rat brainstem after unilateral labyrinthectomy
.
Brain Res
.
1995
Nov
;
700
(
1-2
):
182
90
.
[PubMed]
0006-8993
11.
Meissner
R
.
Behavior of the nystagmus in Menière’s attack
.
Arch Otorhinolaryngol
.
1981
;
233
(
2
):
173
7
.
[PubMed]
0302-9530
12.
Merchant
SN
,
Adams
JC
,
Nadol
JB
 Jr
.
Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops?
Otol Neurotol
.
2005
Jan
;
26
(
1
):
74
81
.
[PubMed]
1531-7129
13.
Molinari
GA
.
Alterations of inner ear mechanisms resulting from application of sodium chloride to the round window membrane
.
Ann Otol Rhinol Laryngol
.
1972
Jun
;
81
(
3
):
315
22
.
[PubMed]
0003-4894
14.
Schuknecht
HF
.
Meniere’s disease: a correlation of symptomatology and pathology
.
Laryngoscope
.
1963
Jun
;
73
:
651
65
.
[PubMed]
0023-852X
15.
Silverstein
H
.
The effects of perfusing the perilymphatic space with artificial endolymph
.
Ann Otol Rhinol Laryngol
.
1970
Aug
;
79
(
4
):
754
65
.
[PubMed]
0003-4894
16.
Smith
PF
,
Darlington
CL
.
Can vestibular compensation be enhanced by drug treatment? A review of recent evidence
.
J Vestib Res
.
1994
May-Jun
;
4
(
3
):
169
79
.
[PubMed]
0957-4271
17.
Smith
PF
,
Darlington
CL
.
The NMDA antagonists MK801 and CPP disrupt compensation for unilateral labyrinthectomy in the guinea pig
.
Neurosci Lett
.
1988
Dec
;
94
(
3
):
309
13
.
[PubMed]
0304-3940
18.
Smith
PF
,
Zheng
Y
,
Paterson
S
,
Darlington
CL
.
The contribution of nitric oxide to vestibular compensation: are there species differences?
Acta Otolaryngol Suppl
.
2001
;
545
:
57
60
.
[PubMed]
0365-5237
19.
Stahle
J
,
Stahle
C
,
Arenberg
IK
.
Incidence of Ménière’s disease
.
Arch Otolaryngol
.
1978
Feb
;
104
(
2
):
99
102
.
[PubMed]
0003-9977
20.
Yamakawa
K
.
Über die pathologische Veränderung bei einem Ménière-Kranken
.
J Otorhinolaryngol Soc Jpn.
1938
;
44
:
2310
2
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.